It seems increasingly likely that at least some of Congress's capital formation bills will soon become law, and that those laws will bode well for private biotechs by creating new fundraising pathways. Read More
Testing for specific mutations has already entered the clinical oncology landscape. Cancer drugs such as Zelboraf (vemurafenib, Roche AG and Daiichi Sankyo Co. Ltd.) and Xalkori (crizotinib, Pfizer Inc.) target patients with specific mutations. Earlier in development, some clinical trials, such as for Exelixis Inc.'s cabozantinib, have focused on specific mutations across a variety of tumor types. Read More
It's been a tough few years for RNAi. Last fall, Roche AG discontinued its preclinical RNAi work, and Novartis AG declined to expand an RNAi partnership with Alnylam Pharmaceuticals Inc. Pfizer Inc. followed suit earlier this year, closing its oligonucleotide therapeutics unit. Read More
FinancingsArGen-X BV raised $37.1 million in a Series B round.Celsion Corp. is raising $15 million in a private placement of stock and warrants.Inhibitex Inc. raised $20 million through an at-the-market offering.NuCana BioMed Ltd. raised $10.5 million in a Series A round for anticancer nucleoside analogues.Oxigene Inc. established a $20 million standby equity purchase agreement. Read More
"I looked at it as the best cost of capital to get this product approved."– Marc Beer, CEO of Aegerion Pharmaceuticals Inc., on his firm's initial public offering, which came at a discount to the original price range"That's why you hear the words 'friends and family.' Whether it's a physical community, an Internet community – one way or another, the relationship has to exist."– David Schechner, managing director at Canaccord Genuity Inc., on how retail investors like to invest in companies with which they have a relationship Read More
An FDA advisory committee is evaluating ways to make the toughest risk evaluation and mitigation strategies more effective and less burdensome.The Senate unanimously approved an amendment to the National Defense Authorization Act that would fund Small Business Innovation and Research and Small Business Technology Transfer through fiscal 2019. Read More
CompanyMonthAmount RaisedAmgen Inc.June$3BEndo Pharmaceuticals Holdings Inc.May$900MValeant Pharmaceuticals International Inc.February$650MDendreon Corp.January$620MRegeneron Pharmaceuticals Inc. Read More
